ClinicalTrials.Veeva

Menu

Maternal Betaine Supplementation During Breastfeeding (BetMilk)

F

Fundació Sant Joan de Déu

Status and phase

Completed
Phase 2
Phase 1

Conditions

Overweight and Obesity

Treatments

Dietary Supplement: Placebo
Dietary Supplement: Betaine

Study type

Interventional

Funder types

Other

Identifiers

NCT04633044
PIC-206-19

Details and patient eligibility

About

Developing more efficient and cost-effective prevention strategies to slow down the worldwide epidemic of obesity and chronic metabolic disease has become a public health imperative. Our previous results in humans demonstrate that lower breast milk betaine levels were associated with faster infant postnatal growth, a strong and potentially modifiable risk factor of future obesity. Betaine is a trimethylated derivative of glycine, which is present in multiple foods and occurs naturally in breast milk. In this study, we will perform a double-blind randomized placebo-controlled pilot clinical study, in which maternal diet will be supplemented with betaine for 3 months during breastfeeding; infant's growth and adiposity will be monitored until 12 months of age, and breast milk composition and gut microbiota analyzed.

Enrollment

47 patients

Sex

Female

Ages

20 to 42 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Maternal Pre-pregnancy BMI between 25 and 40.
  • Willing to exclusively breastfeed for ≥ 3 months
  • Infant gestational age at birth > 37 weeks
  • Infant birth weight > -1 standard deviations
  • Absence of infant disease or malformations at birth

Exclusion criteria

  • Multiple pregnancy
  • Lactose intolerance
  • CBS deficiency (inherited disease)

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

47 participants in 2 patient groups, including a placebo group

Placebo
Placebo Comparator group
Description:
400 mg of lactose daily for 12 weeks
Treatment:
Dietary Supplement: Placebo
Supplement
Experimental group
Description:
400 mg of betaine daily for 12 weeks
Treatment:
Dietary Supplement: Betaine

Trial contacts and locations

1

Loading...

Central trial contact

Carles Lerin, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems